Highlights:
Procedure Growth: Worldwide da Vinci procedures increased by 18% year-over-year, indicating a rising adoption of robotic-assisted surgeries.
System Placements: The company placed 379 da Vinci surgical systems in Q3 2024, a significant increase from 312 systems in the same period last year.
Financial Performance: Revenue for the quarter rose by 17% to $2.04 billion, with GAAP net income reaching $565 million, translating to $1.56 per diluted share.
Intuitive Surgical's (NASDAQ:ISRG) Q3 2024 results reflect a strong upward trajectory in both procedure volume and system placements. The total number of da Vinci surgical systems installed globally increased by 15%, reaching an installed base of 9,539 systems. This expansion highlights the growing recognition and utilization of robotic-assisted surgical systems in various medical fields.
The revenue generated from instruments and accessories also demonstrated robust growth, rising by 18% year-over-year. This increase in revenue was complemented by a notable rise in systems revenue, further underscoring the company's market position and operational strength.
In terms of profitability, Intuitive Surgical reported a GAAP net income of $565 million, equivalent to $1.56 per diluted share. Non-GAAP net income was reported at $669 million, or $1.84 per diluted share. These figures illustrate the company’s ability to maintain strong profitability while scaling operations.
Intuitive Surgical concluded the quarter with an impressive cash and investment balance of $8.31 billion. This substantial financial position provides the company with ample resources for potential future growth opportunities, research and development initiatives, and operational enhancements.
Overall, the third quarter results highlight Intuitive Surgical's ongoing success in the healthcare sector, driven by increasing demand for innovative surgical solutions and a solid commitment to enhancing patient care through advanced technology.